Hodgkin's disease (HD) is one of the most therapysensitive malignant lymphomas and in several long term studies more than 80% of the patients have been considered cured following radiotherapy, chemotherapy or usually a combination of both. Nevertheless, irrespective of age, initial presentation, stage or histologic subgroup, a few patients remain resistant to treatment. These can present, either with initial resistance, an incomplete response to chemotherapy, or early and often multiple, relapses (Teillet-Thiebaud et al., 1984) . For this small group of refractory patients, even though some response can be obtained by changing the therapeutic regimen, survival is very poor (Boccacio et al., 1983) . As HD is highly chemosensitive, several teams have examined the role of high-dose combined modality therapy for these patients, with the support of autologous bone marrow transplantation (ABMT). However, reported results have been rather rare, due to the small number of cases, and are usually part of larger series which include a variety of solid tumours or haematological malignancies (Jagannath et al., 1984; Phillips, 1983a,b; Spitzer et al., 1983; Schmeizer, 1983 
Materials and methods

Patients
Clinical data and prior therapy are summarized in Table I . One case has been previously reported (Gorin et al., 1981) . Ages were between 10 and 45 (median 22). Stages at diagnosis included IA (1), IIA (2), IIB (2), IIIA (2), IIIB (1), and IVB (9). Among the IVB patients, 2 had initial bone marrow involvement and 8 had lung involvement.
Eleven patients were considered to have refractory disease and had never achieved complete remission despite combination chemotherapy and radiotherapy (see details in Table I ). been treated for a median period of 24 months prior to ABMT. At the time of grafting, stages were 11 (3), III (2) and IV (12) ( Table I ). All patients except three (Table I) were progressing at time of ABMT.
Bone marrow freezing and storage All patients had uninvolved bone marrow at the time of harvesting and in vitro purging was not attempted. The harvest was done under general anaesthesia and in all cases bone marrow was cryopreserved according to the usual procedure (Gorin et al., 1983 , Herve et al., 1981 . The number of nucleated cells collected for each case is described in Table II . For some patients, 2 harvests were necessary, due to prolonged previous therapy.
High dose therapy and autologous engraftment Several types of combined modality therapy were used, the details of which are summarized in Table III . Each patient except one received cyclophosphamide and apart from 2, all received either CCNU or BCNU. Nine patients received the TACC or BACT combinations, as often used in non-Hodgkin's lymphomas, and one of these also received TBI (12 Gy). The 8 other patients were given various regimens, as detailed in Table III . Three of these 8 were given TBI (1OGy). Bone marrow was reinfused 48h after the last dose of cyclophosphamide, 12h after TBI and 72h after BCNU or CCNU. Patients received a median of 1.2 x108 nucleated cells kg-1 and were nursed in single rooms until haematologic reconstitution.
Post-treatment evaluation Patients were evaluated at day 30 and thereafter on a monthly basis. They were considered to have had a complete remission only if clinical, radiology and laboratory tests, including the sedimentation rate, became normal. Patients who died less than 30 days after the first day of treatment were not considered evaluable for tumour response unless there was clear evidence of progressive disease or autopsy evidence of remission. No patient received maintenance chemotherapy after ABMT.
Results
Anti-tumour effect (Table IV) Four patients were not evaluable (death on day 4, Cyclophosphamide 40-S0mgkg-'; aracytin 200-400mgm-2; B or CCNU 200-400mgm-2; 6 thioguanine 200-400 mgm -2; vindesine 2.5 mgm -2; vincristine 2mgm-2; adriamycin 60-100mgm-2; caryolysine 6mgm -2; melphalan 100-140mgm-2; procarbazine 200mgm-2; etoposide 100-6mgm-g2. 6, 17 and 20) ; 3 of these, however, showed a partial clinical remission before death. Four patients failed to respond and died within the first month with progressive disease. Nine achieved CR, although 2 of these died from treatment related toxicity (cases 4 and 13), but CR was confirmed at autopsy. Four out of the 8 survivors subsequently relapsed at 3, 4 and 5 months and died within 12 to 17 months. Nevertheless, 3 long-term survivors are presently free of disease, and off therapy for more than 25, 43 and 66 months, respectively. Toxicity (Table II) Haematopoietic reconstitution is detailed in Table II. Seven patients had culture proven sepsis either during the period of aplasia (5) or within the following 3 months (2). Organisms isolated included 2 pseudomonas, 2 escherichia coli, 2 aspergillosis, and 1 cytomegalovirus and were lethal in 6 patients. In 1 case, an acute cardio-respiratory failure developed possibly due to the toxicity of a For electrophoretic mobility analysis, the incubation at room temperature was stopped after 5 min and cells were washed with 0-145 mol/l NaCI, pH 7-2, and measured in cylindrical electrophoresis apparatus as described (Sabolovic et al., 1974) .
RESULTS
Patients with various tumours were tested, together with patients with a variety of other diseases. They included patients without treatment as well as those under treatment. Moreover, some of the patients were followed up for a 5-10 month period and retested at irregular intervals. The controls included normal subjects of both sexes and all ages, normal thymus cells and tonsil lymphocytes. Table I shows the results obtained with all patients tested and Table II shows the evolution of sensitivity to agglutination in 3 individual patients. All 5 fractions of histones (Fl, F2A1, F2A2, F2B and F3) were tested but positive reactions were observed only with F2A1 and sometimes with F2A1, F2B and F3 (Table I) . 76% of all patients were positive in our test compared with negative reactions in 59
